With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

Baird lowered the firm’s price target on Regeneron (REGN) to $652 from $759 and keeps a Neutral rating on the shares. The firm said its Eylea ...

Dimensional Fund Advisors LP boosted its stake in Regeneron Pharmaceuticals by 3% in Q4, totaling over $418 million in ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Pelthos Therapeutics, a Durham-based wholly owned subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND), is combining with ...

Capital International Ltd. CA boosted its Regeneron Pharmaceuticals holdings by 14.5% in Q4, now holding nearly $29.2 million ...

FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is scheduled to begin operations this year.

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...

Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron ...

Holly Springs, North Carolina Wednesday, April 23, 2025, 14:00 Hrs [IST] ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a new study.